809 related articles for article (PubMed ID: 12151535)
1. Pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide inhibit dendritic growth in cultured sympathetic neurons.
Drahushuk K; Connell TD; Higgins D
J Neurosci; 2002 Aug; 22(15):6560-9. PubMed ID: 12151535
[TBL] [Abstract][Full Text] [Related]
2. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
3. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
4. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
5. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
6. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway.
Kim WK; Kan Y; Ganea D; Hart RP; Gozes I; Jonakait GM
J Neurosci; 2000 May; 20(10):3622-30. PubMed ID: 10804204
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms mediating pituitary adenylate cyclase-activating polypeptide depolarization of rat sympathetic neurons.
Beaudet MM; Parsons RL; Braas KM; May V
J Neurosci; 2000 Oct; 20(19):7353-61. PubMed ID: 11007893
[TBL] [Abstract][Full Text] [Related]
8. Functional and molecular diversity of PACAP/VIP receptors in cortical neurons and type I astrocytes.
Grimaldi M; Cavallaro S
Eur J Neurosci; 1999 Aug; 11(8):2767-72. PubMed ID: 10457173
[TBL] [Abstract][Full Text] [Related]
9. Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP.
Leceta J; Gomariz RP; Martinez C; Abad C; Ganea D; Delgado M
Ann N Y Acad Sci; 2000; 921():92-102. PubMed ID: 11193883
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation of the LNCaP prostate cancer cell line maintains the expression and function of VIP and PACAP receptors.
Juarranz MG; Bolaños O; Gutiérrez-Cañas I; Lerner EA; Robberecht P; Carmena MJ; Prieto JC; Rodríguez-Henche N
Cell Signal; 2001 Dec; 13(12):887-94. PubMed ID: 11728828
[TBL] [Abstract][Full Text] [Related]
11. Pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal peptide (VIP) stimulate interleukin-6 production through the third subtype of PACAP/VIP receptor in rat bone marrow-derived stromal cells.
Cai Y; Xin X; Shim GJ; Mokuno Y; Uehara H; Yamada T; Agui T; Matsumoto K
Endocrinology; 1997 Jun; 138(6):2515-20. PubMed ID: 9165043
[TBL] [Abstract][Full Text] [Related]
12. The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor.
Sano H; Miyata A; Horio T; Nishikimi T; Matsuo H; Kangawa K
Regul Pept; 2002 Nov; 109(1-3):107-13. PubMed ID: 12409222
[TBL] [Abstract][Full Text] [Related]
13. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
[TBL] [Abstract][Full Text] [Related]
14. Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages.
Sun W; Tadmori I; Yang L; Delgado M; Ganea D
J Neuroimmunol; 2000 Jul; 107(1):88-99. PubMed ID: 10808055
[TBL] [Abstract][Full Text] [Related]
15. Maxadilan specifically interacts with PAC1 receptor, which is a dominant form of PACAP/VIP family receptors in cultured rat cortical neurons.
Tatsuno I; Uchida D; Tanaka T; Saeki N; Hirai A; Saito Y; Moro O; Tajima M
Brain Res; 2001 Jan; 889(1-2):138-48. PubMed ID: 11166697
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide receptors in rat intrinsic cardiac neurons.
DeHaven WI; Cuevas J
Neurosci Lett; 2002 Aug; 328(1):45-9. PubMed ID: 12123856
[TBL] [Abstract][Full Text] [Related]
17. Multiple signal pathways coupling VIP and PACAP receptors to calcium channels in hamster submandibular ganglion neurons.
Kamaishi H; Endoh T; Suzuki T
Auton Neurosci; 2004 Mar; 111(1):15-26. PubMed ID: 15109935
[TBL] [Abstract][Full Text] [Related]
18. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Carrero I; Cavallaro S; Roman F; Hueso C; Travali S; Lopez-Fraile N; Guijarro LG; Prieto JC
Endocrinology; 1996 Jul; 137(7):2815-22. PubMed ID: 8770902
[TBL] [Abstract][Full Text] [Related]
19. Identification and functional properties of the pituitary adenylate cyclase activating peptide (PAC1) receptor in human benign hyperplastic prostate.
Solano RM; Carmena MJ; Busto R; Sánchez-Chapado M; Guijarro LG; Prieto JC
Cell Signal; 1999 Nov; 11(11):813-9. PubMed ID: 10617284
[TBL] [Abstract][Full Text] [Related]
20. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain.
Joo KM; Chung YH; Kim MK; Nam RH; Lee BL; Lee KH; Cha CI
J Comp Neurol; 2004 Aug; 476(4):388-413. PubMed ID: 15282712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
